期刊文献+

正肝化症汤治疗中晚期原发性肝癌临床观察 被引量:10

Clinical observation of zhenggan huazheng decoction on advanced primary liver cancer
下载PDF
导出
摘要 目的:观察正肝化症汤联合西药治疗中晚期原发性肝癌的临床疗效.方法:将96例中晚期原发性肝癌患者按照随机数字表法随机分成两组,每组各48例.对照组予保肝及对症支持治疗,治疗组在对照组治疗基础上加服正肝化症汤(灵芝、白术、茯苓、茵陈、丹参、赤芍、白花蛇舌草),每日1剂,分2次口服.两组均以治疗120日为1个疗程.结果:治疗组近期疗效总有效率为91.67% (95% CI=79.60% ~97.66%),对照组为54.17% (95% CI=40.04% ~ 68.24%),两组综合疗效比较(u=3.536 7,P=0.000 6),差异有显著性意义;治疗组2年生存率为54.17% (95% CI =40.07% ~ 68.27%),对照组为29.17% (95% CI=16.31% ~42.03%),两组比较(x2=6.171 4,P<0.05),差异有显著性意义;治疗组治疗后肝功能指标和总胆红素明显降低,且明显低于对照组(P<0.01).结论:正肝化症汤联合西药治疗中晚期原发性肝癌的疗效优于单纯西药治疗的证据明显,其收益为OR =0.11 (95%CI =0.03 ~0.35),NNT =3(95%CI=1.81 ~5.07);其两年生存率的收益为OR=0.35 (95%CI =0.15 ~0.81),NNT=4(95%CI =2.24~ 19.94);且可促进肝功能恢复. Objective: To observe the clinical effect of zhenggan huazheng decoction combined with western medicine on advanced primary liver cancer. Methods : 96 cases of patients with advanced primary liver cancer were randomly divided into two groups according to rand number table method, 48 cases in each group. The control group was given the hepatoprotective, anti - symptomatic and supportive treatments. On the basis of treatment of control group, the treatment group were treated additionally with zhenggan huazheng decoction (ganodermalucid- um, atractylodes, poria, radix salviaemiltiorrhizae, radix paeoniaerubra, herba artemisiae scopariae, hedyotisdiffusa), 1 agent per day , 2 times a day orally. The two groups were treated for 1 course of 120 days. Results: The total effective rate of treatment group was 91.67% (95% CI =79.60% -97.66% ) ,while the control group was 54. 17% (95% CI =40.04% -68.24% ) ; compared the comprehensive effects of two groups (u =3.536 7, P = 0. 0006) , the difference had remarkable significance. The 2 year survival rate of treatment group was 54. 17% (95% CI =40.07% -68.27% ) ,while the control group was 29. 17% (95% CI = 16. 31% -42.03% ) ;compared two groups (X2 = 6. 1714, P 〈 0.05 ), the difference had remarkable significance. After treatment, the liver function indices and total bilirubin in treatment group were significantly lower than those in control group (P 〈 0. 01 ). Conclusion : The clinical effect of zhenggan huazheng decoction combined with western medicine on advanced primary liver cancer is better than simply with western medicine, which has obvious evidences. Its benefits is OR = 0. 11 (95 % CI = 0. 03 - 0.35 ), NNT = 3 (95 % CI = 1.81 - 5.07 ). The benefits of its two - year survival rate is OR =0. 35 (95% CI =0. 15 -0. 81 ), NNT =4 (95% CI =2.24 - 19. 94), and can promote the recovery of liver function.
出处 《山西中医》 2016年第2期13-15,28,共4页 Shanxi Journal of Traditional Chinese Medicine
基金 2010年度湖北省教育厅高等学校青年教师深入企业行动计划项目(编号:XD2010305)
关键词 原发性肝癌 正肝化症汤 中医药疗法 primary liver cancer, zhenggan huazheng decoction, Traditional Chinese Medicine
  • 相关文献

参考文献18

二级参考文献80

共引文献339

同被引文献122

引证文献10

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部